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Abstract: Jellyfish have emerged as a source of next genera-
tion collagen that is an attractive alternative to existing sour-
ces, such as bovine and porcine, due to a plentiful supply
and providing a safer source through lack of bovine spongi-
form encephalopathy (BSE) transmission risk and potential
viral vectors, both of which could be transmitted to humans.
Here we compare collagen implantable sponges derived for
the first time from the Rhizostoma pulmo jellyfish. A further
novelty for the research was that there was a comparison for
sponges that were either uncrosslinked or crosslinked using
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochlo-
ride (EDC), and an assessment on how this affected resorp-
tion, as well as their biocompatibility compared to bovine
type I collagen sponges. The scaffolds were prepared and
examined using sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS PAGE) and scanning electron micros-
copy (SEM). The samples were implanted in adult male
Wistar rats for in vivo experimentation. Both crosslinked and
uncrosslinked jellyfish collagen sponges showed a significant
reduction in histopathology scores over the course of the study,
whereas the bovine collagen sponge scores were not signifi-
cantly reduced. Both jellyfish collagen sponges and the bovine
sponge were tolerated well by the hosts, and a recovery was
visible in all samples, suggesting that R. pulmo jellyfish-derived
collagen could offer compelling biocompatibility with wound
healing applications. We also demonstrate that noncrosslinked
samples could be safer with better resorption times than cross-
linked samples. VC 2017 The Authors Journal of Biomedical Materials
Research Part B: Applied Biomaterials Published by Wiley Periodicals,
Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1524–1533, 2018.
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INTRODUCTION
Collagens are the main group of structural proteins to be
found in the extracellular matrix (ECM) and are the most
abundant protein found in animals, providing between 25
and 35% of the whole body protein count. Collagens share
the characteristic triple helix structure of Gly-X-Y repeats,
where X can be any amino acid and Y is often proline or
hydroxyproline. The individual chains form a left-handed
helix, and the three chains wind around one another in a
right-handed super helix.1,2 This structure makes the colla-
gen ﬁbers insoluble with high tensile strength.3 Collagen is
a highly versatile biomaterial, which has a wide range of
applications, and is particularly suited to a wide range of in
vivo applications due to its low immunogenicity.4–6 These in
vivo applications include wound dressings,7 artiﬁcial tissue
and organ production,8 cartilage tissue regeneration,9,10
drug delivery systems,11 and biomedical engineering.12
Collagen has been extracted from a range of sources, but
is commonly obtained from bovine, porcine, and equine
sources for in vivo use.13 However, these sources have prob-
lems with bovine spongiform encephalopathy (BSE), other
transmittable spongiform encephalopathies (TSEs), and
potential viral vectors that could be transmissible to
humans.14,15 More recently, jellyﬁsh have emerged as a
source of collagen that is an attractive alternative to existing
sources due to a plentiful supply16 and a safer source
through lack of BSE risk and potential viral vectors.17
This study aimed at assessing the biocompatibility of
two dried jellyﬁsh collagen implantable sponges, which
either remained uncrosslinked or were crosslinked using 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochlo-
ride (EDC) and comparing it to the compatibility of control
devices, namely a bovine type I collagen sponge implanted
for 1, 2, 3, or 4 weeks in rats. EDC has been utilized as an
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alternative crosslinking agent for collagen to replace glutar-
aldehyde,18 which causes a number of problems when
implanted including calciﬁcation of surrounding tissue.19
The study also investigated whether the use of EDC as a col-
lagen crosslinking agent is necessary for adequate wound
stability and its impact on sponge efﬁcacy when implanted.
To our knowledge this represents the ﬁrst instance in the
ﬁeld of the testing of native collagen samples derived from
R. pulmo being directly compared with bovine type I colla-
gen sponges in vivo as well as investigating the effects of
EDC crosslinking on jellyﬁsh collagen performance in vivo.
Some species of jellyﬁsh have been previously trailed in
vitro and in vivo17,20; however, it is important to assess jel-
lyﬁsh collagen on a species basis, and not to take for
granted that all jellyﬁsh collagen will behave uniformly. Dif-
fering jellyﬁsh species have varying masses, water content,
habitat temperature, environments as well as many other
factors, and any individual factor could have an impact on
the collagen characteristics and the potential immunogenic-
ity of the collagen.21 Due to the makeup of nematocysts,
namely their mini collagen ﬁber content,22–24 the toxicity of
the species should also be considered, and it is for this rea-
son that the R. pulmo jellyﬁsh was used in these experi-
ments, which has been shown to be mildly toxic to cells in
vitro,25,26 but does not cause fatalities in humans unlike the
Chironex ﬂeckeri found in waters surrounding Australia,27
and the Chironex yamaguchii recently discovered to have
caused numerous deaths in Japan.28
METHODS
SDS PAGE analysis of collagen solution
Jellyﬁsh collagen obtained from R. pulmo was provided by
Jellagen, and protein purity was analyzed using sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS
PAGE). Brieﬂy, 7.5 mL of 3 ng/mL collagen dissolved in ace-
tic acid at 48C was mixed with 2.5 mL NuPAGEVR LDS Sample
Buffer (4X) (Life Technologies, UK). This mixture was then
heated at 708C in an incubator to reduce the collagen.
SDS running buffer was prepared using 50 mL 20X
NuPAGEVR Tris Acetate SDS Running Buffer added to
950 mL deionized water. NuPAGEVR Tris Acetate Mini Gels
were loaded into the holding clamp frame (Jencons, UK)
and the running buffer added accordingly: 200 mL inner
chamber, 600 mL outer chamber. The samples were then
loaded alongside repeats of reference BenchmarkTM
Unstained Protein Ladder (Novex, UK) and the gel ran at
150 V using a concord power pack. Observed current ran
from starting 45 mA to ﬁnal 27 mA. After running, the gel
was removed and placed into a tray for staining.
The gel was stained using a Colloidal Blue staining kit
(Invitrogen) based on work described by Neuhoff et al.29
The gel was initially stained using a mixture of Stainer A,
composed of ammonium sulfate in a phosphoric acid solu-
tion, and Stainer B containing the Coomassie Brilliant Blue
(CBB) G-250 Stain create a colloidal suspension. Ultrapure
water and methanol was added, dissolving the colloidal sus-
pension, allowing complete diffusion of the dye. This solu-
tion was left to shake for a minimum of 3 h and then
decanted and replaced with ultrapure water overnight to
remove any dye not bound to the protein bands. The
stained gels were then imaged and examined using ImageJ
software.
Collagen sponge preparation
Freeze drying. The collagen solution was lyophilized to pro-
duce implantable collagen sponges for testing. To achieve
this, samples were ﬁrst aliquoted into 5 mL discs in six well
plates (Corning, UK) and frozen at 2208C for 24 h, and then
transferred to 2808C, as Lyostat analysis of the collagen sol-
utions showed an onset of collapse of 232.58C (Carried out
by Biopharma Technologies, UK). The samples were trans-
ferred to a freeze drier (Scanvac CoolSafeTM) for drying.
Once pressure was at 100 mbar and shelf temperature was
measured at 2308C, the primary drying stage of the process
was carried out for 100 h. Following this, shelf temperature
was raised to 1208C for 15 h for the secondary drying
stage. Samples were then removed from the drier and
weighed before being stored in sealed containers with silica
pouches at 48C until use.
When dry, small fragments were examined using scan-
ning electron microscopy (SEM) by coating in a 5 nm layer
of chromium before being examined by SEM using a Hitachi
S4800 FEG SEM at an acceleration voltage of 1 kV and emis-
sion current of 9.8 mA. Micrographs were taken with a mag-
niﬁcation of 1803 using the lower detector with images
being analyzed using ImageJ software.
Crosslinking of implants. In order to produce the cross-
linked samples 12 of the dried sponges were crosslinked by
immersing them in a 1% solution of EDC (Sigma Aldrich) in
ethanol (Fisher Scientiﬁc, UK) for 2 h. The crosslinking solu-
tion was then removed from the sponges and they were
then soaked in water for 24 h. These sponges were cut to
provide 48 crosslinked samples and 48 noncrosslinked sam-
ples. Control bovine type I collagen samples were purchased
as ready-made sponges from Cell Systems (Germany). These
were cut to provide 20 bovine type I control sponge sam-
ples. Samples were provided to KWS Biotest (Bristol, UK)
who performed the in vivo rat study and provided results
for further analysis. All samples were soaked for 24 h in
ethanol to sterilize and lyophilized.
Sterilization. To check sterility of the sample solution prior
to lyophilization and implantation, samples were taken from
stock solutions and from sponges which were redissolved in
0.5 M AcOH and were plated on agar petri dishes using
1 mL of solution at a concentration of 8.25 mg/mL. The
plates containing collagen were incubated at either 20 or
378C to check for microbial growth on the plates over a 24
and 72 h time period. Further to this, 5 mL of sample was
prepared as above and was added to 45 mL of maximum
recovery diluent (MRD) and incubated for 24 h before plat-
ing out in the same manner as before. Any potential growth
was detected from these protocols using visual analysis of
the presence or absence of colonies. The use of solutions
and sponges past this point was carried out in sterile
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conditions in a Class II hood, including all ethanol soaking
sterilization protocols.
In vivo experimental outline
All animal experiments comply with the ARRIVE guidelines
and were carried out in accordance with the U.K. Animals
(Scientiﬁc Procedures) Act, 1986 and associated guidelines,
EU Directive 2010/63/EU for animal experiments.
Thirty-two adult male Wistar rats were randomly allo-
cated to experimental groups and allowed to acclimatize for
1 week. Collagen sponges were assigned to one of three
groups, jellyﬁsh collagen crosslinked sponges (JEL #01)
where n512, jellyﬁsh collagen noncrosslinked sponges (JEL
#02) where n5 12 and control bovine type I collagen
(CON) where n55. On day 0, each animal was implanted
with up to three devices (collagen sponges). Implantation
was performed under isoﬂurane anesthesia. The back skin
was clipped then disinfected. A rostro caudal incision was
performed in the back skin, starting at least two centi-
meters from the neck. Subcutaneous pockets were opened
by blunt dissection, on each side of the midline. The dis-
tance between each device and the midline incision was no
less than two centimeters. The distance between each
implant on a given side was no less than two centimeters.
The position of the implants was randomized between ani-
mals. On day 7 (group 1), day 14 (group 2), day 21 (group
3), and day 28 (group 4), animals were culled and the
implants, together with the surrounding connective tissues,
were dissected out. Gross morphological observations were
made and pictures were taken when applicable. Connective
tissues were stored in tissue ﬁxative until histopathological
analysis. A semiquantitative scoring system was used to
evaluate the tissue response and sponge resorption.
Treatment groups and dosages. Animals were split into
four experimental groups, representing termination dates in
7-day intervals. All animals were implanted with sponges
on day 0. In each group, three animals were implanted with
JEL #01 and JEL #02 implants only, while ﬁve animals in
each group received all implants (JEL #01, JEL #02, and
CON). This is shown in Table I.
Nonspeciﬁc clinical observations. From day 0 until the end
of the experiment, animals were checked daily for nonspe-
ciﬁc clinical signs to include abnormal posture (hunched),
abnormal coat condition (piloerection), and abnormal activ-
ity levels (reduced or increased activity).
Bodyweights. From day 0 until the end of the experiment,
animals were weighed three times per week. Data were
graphed (mean6 SEM). Raw and analyzed data are
provided.
Gross morphological observations. At necropsy, gross mor-
phological observations were made when applicable. The
midline incision was observed as well as the connective tis-
sue surrounding each implant. Gross signs of inﬂammation
such as redness and/or neovascularization are reported.
When applicable, representative pictures were taken.
Histopathology. Histopathology examinations were con-
ducted under a double blind study design by an external
histopathologist (KWS Biotest, Bristol) without knowledge
of the experimental protocol and the differences between
the four groups and three sites sampled to avoid bias
between jellyﬁsh and control samples.
Samples of residual implant (where identiﬁable) and
surrounding connective tissue were processed, embedded in
parafﬁn wax and sections were prepared. Sections were
stained with hematoxylin and eosin (H&E) or with Masson’s
trichrome stains in order to visualize any cellular inﬁltrate
and structural changes as well as the presence of collagen,
respectively. One section per sample was analyzed for each
of the stains. Tissue morphology and pathological changes
were investigated, which monitored the presence of inﬂam-
matory cells (neutrophils, eosinophils, lymphocytes, macro-
phages, and/or giant cells) which surrounded or were
within the implant. Where these were clearly identiﬁable,
ﬁbrous encapsulation, neovascularization, and/or necrosis
were recorded. For each sample, a total histopathology score
was calculated by adding the inﬂammation score, the ﬁbro-
sis score, the necrosis score, and the neovascularization
score. Each criterion was scored by a qualiﬁed histopatholo-
gist, blind to the experimental design, using a semiquantita-
tive scoring system on a ﬁve-point scale: (0) absence, (1)
slight, (2) moderate, (3) marked, and (4) severe. The
amount and distribution of collagen within the implant was
assessed and measured quantitatively by the presence of
the bright red staining of collagen sponge within each sample
when using H&E stain. Samples were also scored for signs of
sponge resorption using the same semiquantitative scale. Data
were graphed (mean6 SEM). Raw and analyzed data are pro-
vided. Histopathology scores were analyzed by Kruskal-Wallis
test for nonparametric data followed by Dunn’s post-test for
multiple comparisons between experimental groups. Total
TABLE I. Assignment of Animals to Experimental Groups With Termination Dates. Animals Were Split Into Four Experimental
Groups, Differentiated by Termination Date, As Shown in the Table. 8 JEL#01 and JEL#02 Were Present in Each Group,
Whereas There Were Only Five CON in Each Group, Meaning Three Animals in Each Group Only Had the Two Jellyfish
Collagen Implants
Group Experimental Group Sponge Implantation (Day 0) Termination
1 n5 8 Subchronic 1 week JEL #01 n5 8, JEL #02 n5 8, CON n5 5 Day 7
2 n5 8 Subchronic 2 weeks JEL #01 n5 8, JEL #02 n5 8, CON n5 5 Day 14
3 n5 8 Subchronic 3 weeks JEL #01 n5 8, JEL #02 n5 8, CON n5 5 Day 21
4 n5 8 Subchronic 4 weeks JEL #01 n5 8, JEL #02 n5 8, CON n5 5 Day 28
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histopathology scores were calculated by adding the inﬂamma-
tion, ﬁbrosis, necrosis and neovascularization scores.
RESULTS
SDS PAGE
SDS PAGE analysis of the collagen samples showed distinc-
tive collagen a1 and a2 bands at 105 and 92 kDa,
respectively; b chain expression as well as the presence of
g chains. These are shown in lanes 7–10 of Figure 1.
The jellyﬁsh derived collagen that was examined using
SDS PAGE showed the distinct a1 and a2 chains associated
with acid solubilized collagen, as well as b and g chains,
which indicates the presence of both acid soluble collagen
monomeric chains, as well as a portion of semisoluble colla-
gen in solution which was not cleaved by digestion or
removed when samples were centrifuged prior to testing
for SDS PAGE.
Freeze drying
Drying of collagen samples was conducted and residual
moisture analysis showed between 2 and 5% in all samples.
SEM micrographs of a small section of collagen sponge as
shown in Figure 2 demonstrate that collagen sponge struc-
ture is assembled into sheets with ﬁbers between the
sheets, giving an open pore structure.
In vivo experimental results
Nonspeciﬁc clinical observations. From day 0 until the end
of the experiment, animals were checked daily for nonspe-
ciﬁc clinical signs. Animals did not show any nonspeciﬁc
signs such as abnormal posture (hunched), abnormal coat
condition (piloerection), or abnormal activity levels
(reduced or increased activity).
Bodyweights. Bodyweight loss was not observed in any of
the experimental groups for the duration of the study, as
demonstrated in Figure 3 for each group of weeks 1–4.
Gross morphological observations. Prior to implantation,
JEL #01 matrices were observed to have a very soft consis-
tency and appeared wet whereas JEL #02 and CON matrices
appeared dry.
One week after implantation, swelling was visible under
the skin of some of the animals. On day 11 and 12, three
animals were culled in order to identify the cause of the
swelling. In each of the three animals, a large pocket ﬁlled
with blood was observed to cause the swelling. The pocket
initiated from the area where implants JEL #01 had been
inserted. Microbiological analysis of samples taken from
these animals showed absence of bacterial contamination.
The presence of the blood was attributed to a tissue reac-
tion to the implant and/or to trace amounts of ethanol
remaining in the porous matrices. Animals were monitored
at weekly intervals for the visible presence of the implants,
vascularization or tissue thickening. These observations are
outlined in Table II.
Histopathology. Many of the sections lacked any evidence
of the presence of the collagen implant, which has a distinc-
tive bright red appearance when H&E stain is used, but this
FIGURE 1. SDS PAGE of collagen extracted from R. pulmo showing
collagen bands present in solution. Lanes 1 and 2: Benchmark high
molecular weight protein ladder. Lanes 3–6: noncollagenous proteins
removed from solution prior to testing. Lanes 7–10: Collagen solution
containing a1, a2, b, and g collagen chains.
FIGURE 2. SEM micrograph of the collagen sponge showing a sheet
structure with the presence of fibers. Acceleration voltage of 2 kV and
emission current of 8.2 mA, magnification 303 taken using a mixture
of upper and lower detectors of the Hitachi S4800 FEG SEM.
FIGURE 3. Bodyweights. Data are presented as mean6SEM of per-
centages of the initial (day 0) bodyweights.
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could have been because the area of tissue containing any
remaining sponge was not sampled.
The least resorption of the collagen implants was seen
in group 1 on day 7, where what appeared to be an entire
sponge was often present within a cystic cavity lined by
granulomatous inﬂammation and granulation tissue. This is
shown in Figure 4.
In group 2, on day 14, there was greater evidence of
sponge resorption, with areas of residual sponge inﬁltrated
by and surrounded by macrophages and multinucleate giant
cells. JEL #02 appeared to show cystic cavities surrounding
the collagen sponge in some animals, whereas this was not
present in observed JEL #01 and CON samples. This is
shown in Figure 5.
Only one animal in group 3 (on day 21) had evidence of
resorbing the collagen sponge, but other animals in this
group had evidence of subcutaneous hemorrhage and
resorption of blood by hemosiderophages. A CON sample
was sectioned showing a blood ﬁlled cystic cavity present
surrounding the sponge. These results are shown in Figure
6. JEL #02 sections from this group were found to not con-
tain any of the collagen sponges and so they are not shown.
Some animals in group 4 (on day 28) had even greater
resorption of sponge with relatively small residual foci of
inﬂammation and sponge remnants—but a greater number
of animals in this group had no changes in the sampled tis-
sues at all. This is shown in Figure 7.
Histopathology scores. There was no signiﬁcant difference
between experimental groups: the histopathology scores
observed around JEL #01, JEL #02, and CON implants did
not differ on a given day. The histopathology scores
observed around the implants decreased with time. The dif-
ference in scores between day 7 and day 28 was statistically
signiﬁcant for JEL #01 and JEL #02 implants (p< 0.05).
This is shown in Figure 8.
Inﬂammation scores did not differ between experimental
groups on a given experimental day or between experimen-
tal days for a given experimental group. Fibrosis scores did
not differ between experimental groups on a given experi-
mental day or between experimental days for a given exper-
imental group. Necrosis scores were low on day 7 and
returning to zero by day 14 for the JEL #01 and CON
groups, and by day 21 for the JEL #02 group. Scores did
not differ between experimental groups on a given experi-
mental day or between experimental days for a given exper-
imental group. This is shown in Figure 9.
Statistical methods
All graphs use6 standard error of the mean to indicate sta-
tistical signiﬁcance. Histopathology scores were analyzed by
Kruskal–Wallis test for nonparametric data followed by the
Dunn’s post-test for multiple comparisons with a p values of
<0.05 being considered statistically signiﬁcant.
DISCUSSION AND CONCLUSIONS
Discussion
Subcutaneous implantation of JEL #01 or JEL #02 collagen
sponges induced histopathological changes including inﬂam-
mation, ﬁbrosis, necrosis, and neovascularization. The sever-
ity of the histopathological changes was greater on the
earliest time point studied (day 7). The severity of the histo-
pathological changes decreased as soon as day 14 and kept
decreasing until the end of the experiment on day 28. Histo-
logical changes throughout the experiment were very simi-
lar throughout the three test groups, with inﬂammation and
ﬁbrosis being visible throughout the time period, with both
JEL #01 and JEL #02 both showing signiﬁcant decreases
throughout, whereas CON did not display a signiﬁcant drop
in ﬁbrosis. All samples displayed no necrosis by the end of
the study, and only JEL #02 showed any neovascularization
at day 28, however all three groups were signiﬁcantly lower.
These results show good acceptance of the jellyﬁsh col-
lagen implants by the host. Lack of necrosis shows that
there are no toxins or infection that is causing cell death,
while ﬁbrosis and neovascularization are indicative of
TABLE II. Summary of Gross Morphological Observations,
Taken at Weekly Intervals. Data Represents the Number of
Specimens Which Displayed Visible Signs of Implant, Vascu-
larization, and Tissue Thickening. Visible Signs of These
Decreased Throughout the Experiment in All Three Implants
Day Implant Observations Occurrence
Day 7 JEL #01 Implant still visible 87.5% (7/8)
Vascularization 62.5% (5/8)
Tissue thickening 12.5% (1/8)
JEL #02 Implant still visible 87.5% (7/8)
Vascularization 75.0% (6/8)
Tissue thickening 25.0% (2/8)
Control Implant still visible 100% (5/5)
Vascularization 60.0% (3/5)
Tissue thickening 20.0% (1/5)
Day 14 JEL #01 Implant still visible 60.0% (3/5)
Vascularization 20.0% (1/5)
Tissue thickening 20.0% (1/5)
JEL #02 Implant still visible 60.0% (3/5)
Vascularization 20.0% (1/5)
Tissue thickening 20.0% (1/5)
Control Implant still visible 60.0% (3/5)
Vascularization 0% (0/5)
Tissue thickening 40.0% (2/5)
Day 21 JEL #01 Implant still visible 37.5% (3/8)
Vascularization 12.5% (1/8)
Tissue thickening 25.0% (2/8)
JEL #02 Implant still visible 12.5% (1/8)
Vascularization 50.0% (4/8)
Tissue thickening 25.0% (2/8)
Control Implant still visible 20.0% (1/5)
Vascularization 60.0% (3/5)
Tissue thickening 20.0% (1/5)
Day 28 JEL #01 Implant still visible 0% (0/8)
Vascularization 12.5% (1/8)
Tissue thickening 0% (0/8)
JEL #02 Implant still visible 0% (0/8)
Vascularization 0% (0/8)
Tissue thickening 0% (0/8)
Control Implant still visible 20.0% (1/5)
Vascularization 20.0% (1/5)
Tissue thickening 0% (0/5)
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healing30 and inﬂammation is dropping throughout the
study, as the foreign body is broken down and reabsorbed.
The signiﬁcant reduction in both JEL #01 and JEL #02 his-
topathology scores between weeks 4 and 1 suggest good
bioequivalence and biocompatibility. These histopathological
results are generally in line with similar studies conducted.
Granulation and ﬁbrosis was visible in studies conducted by
Anselme et al.,31 and Alpaslan et al.,32 at around day 7. At
around 30 days, both studies observed a sizeable reduction
in the collagen present and ﬁbrous tissue surrounding the
remaining fragments. Both of these studies, however, contin-
ued past day 30 and ended at day 4532 and after 3
months.31 The trend of collagen reduction continued over
these timeframes and it seems likely that this would be the
case for jellyﬁsh collagen.
The changes induced by the implants did not differ sig-
niﬁcantly in severity from the changes induced by control
bovine collagen matrices. This is encouraging, as bovine col-
lagen is well known to be of low antigenicity and tolerated
well, and it is incorporated into a wide range of medical
FIGURE 4. Histology sections from group 1 (HE stains). (a) JEL #01 cystic cavity containing portion of collagen sponge and lined by inflamma-
tion and fibrosis. (b) JEL #02 area of granulation with prominent neovascularization. (c) CON collagen sponge within a cystic cavity surrounded
by circumferential granulomatous inflammation and fibrosis.
FIGURE 5. Histology sections from group 2. (a) JEL #01 (HE stain) focus of granulomatous inflammation and fibrosis centered on remnants of
collagen sponge. (b) JEL #02 (Masson’s stain) cystic cavity filled with blood and fibrin and lined by granulomatous inflammation and granula-
tion tissue. (c) CON (HE stain): Discrete granulomatous focus centered on residual fragments of collagen sponge.
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applications and devices13,33,34 and means that the jellyﬁsh
collagen implants are showing suitability for the same medi-
cal uses.
The jellyﬁsh derived collagen that was examined using
SDS PAGE showed the distinct a1 and a2 chains associated
with acid solubilized collagen, as well as b and g chains,
which indicates the presence of a portion of semi-insoluble
collagen in suspension. This may in part be why the non-
crosslinked collagen was able to remain structurally com-
plete during and following implantation. The banding
pattern observed in Figure 1 is supported by other
extracted marine collagens such as the skin of striped cat-
ﬁsh, which also display clear a1, a2, b, and g band patterns
in equivalent locations.35 This conforms to both mammalian
collagens and collagens from cartilaginous ﬁsh, which dis-
play the same banding pattern at similar molecular
weights.36,37
This study was carried out using sponges which were
produced and stored using lab based techniques and set-
tings, involving creating sponges in nonsterile conditions
FIGURE 6. Histology sections from group 3 (HE stain). (a) JEL #01 focus of granulomatous inflammation and fibrosis. Fragments of collagen
sponge are adjacent to the focus (b) JEL #01 granulomatous inflammation with a cluster of giant cells surrounding foreign material. Eosinophils
and lymphoplasmocytic cells are scattered throughout. (c) CON blood filled cystic cavity with narrow lining adjacent to discrete granulomatous
focus centered on remnants of collagen sponge.
FIGURE 7. Histology sections from group 4 (Masson’s stain). (a) JEL #01 very small discrete focus within subcutis containing multinucleate giant
cells surrounding residual fragments of collagen sponge. (b) JEL #02 cystic cavity containing a fragment of residual collagen sponge, blood,
and fibrin; surrounded by granulomatous inflammation and fibrosis. (c) CON small remnant of collagen sponge imbedded in a diffuse region of
inflammation and fibrosis with cystic spaces.
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and then using an ethanol sterilization step. This led to
trace ethanol being present in some implants when
implanted, and caused large pockets of swelling to be pre-
sent on some animals. Samples were tested for sterility
before implantation and found not to be infected, so this
can be conﬁdently ruled out as the cause of the swelling
pockets. Three animals were culled on days 11 and 12 to
investigate this swelling, and it was found to be a large
pocket of blood which was attributed to trace ethanol being
present in the samples. To improve on this, it would be rec-
ommended for future sample preparation to be carried out
with more rigorous focus on sterilization of the samples
prior to implantation, using a technique such as ﬁltration,
gamma irradiation or E beam technologies. It is also
acknowledged that this study used a small test population,
which was further reduced by the need to cull three
FIGURE 8. Total histopathology scores: (a) Scatterplot. Horizontal bars represent mean; vertical bars represent SEM. (b) Total histopathology
scores presented as mean6SEM. Total scores reduced over time, with JEL #01 and JEL #02 showing a significant difference in scores between
day 7 and day 28 (p< 0.05).
FIGURE 9. Mean inflammation, fibrosis, necrosis, and neovascularization scores 6SEM. (a) Inflammation scores in all three groups are signifi-
cantly lower at day 28 than day 7 (p< 0.05). There were no differences between the experimental groups. (b) Fibrosis scores in JEL #01 and JEL
#02 are significantly lower at day 28 than day 7 (p<0.05). No significant difference is shown in the control group. (c) Necrosis scores in all JEL
#01 and control groups are zero by day 14, however JEL #02 still has some necrosis present. (d) Neovascularization scores in all three groups
are significantly lower at day 28 than day 7 (p< 0.05). There were no significant differences between the experimental groups.
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animals early, and that the number of control samples was
not equal to jellyﬁsh collagen samples.
Jellyﬁsh collagen extracted from Rhopilema asamushi has
been shown to denature at temperatures above 28.88C,38
and collagen from R. pulmo denatures at 28.98C which can
be raised to 338C by crosslinking with EDC.39 Crosslinking
of collagen sponges, including the use of EDC has been
shown to induce a pro inﬂammatory response, including
macrophage activation and an increase of pro inﬂammatory
cytokine release, despite a lack in understanding as to the
mechanisms in which this occurs.40 The JEL #01 samples
which remained uncrosslinked served to demonstrate that
despite this temperature instability, no signiﬁcant disadvan-
tage was shown to exist in this study, and that they could
be more biocompatible and better suited for in vivo applica-
tions due to their enhanced ability to be absorbed and inte-
grated with the surrounding tissue. To improve observation
of minor factors such as this, and to determine whether the
presence of the semi-insoluble collagen affected the stability
of the uncrosslinked sponges, a higher test population
should be used to improve statistical analysis, and more
quantitative biological and genetic testing could be carried
out on the surrounding tissues after treatment has occurred.
Alternative crosslinking reagents/methods could also be
used to optimize mechanical properties while maintaining
good biocompatibility.
Research on the in vivo immunological effects of collagen
extracted from jellyﬁsh has previously been carried out,
with data suggesting that jellyﬁsh collagen stimulates the
production of Ig by mouse lymphocytes from the spleen and
Peyer’s patch.41 Unfortunately, this group obtained collagen
by heating the jellyﬁsh extract to 1218C which would dena-
ture any native collagen into gelatin and give incomparable
data to native extracted collagen used in this study. Avail-
able literature on pure, native collagen as used in this study
is relatively sparse, however one of the few studies that can
be compared against is Song et al.17 who found that jellyﬁsh
collagen sponges produced an immune response comparable
to bovine collagen and gelatin. The results from our study
support this ﬁnding, and further also show that both jelly-
ﬁsh collagen samples showed a signiﬁcant reduction in his-
topathology scores whereas the bovine collagen did not,
suggesting that perhaps jellyﬁsh collagen was tolerated
slightly better. Further research into the immunological
pathways which are upregulated in the presence of R. pulmo
collagen should be conducted. Song et al.17 did not compare
between crosslinked and un crosslinked samples, which we
demonstrate can play a large part in the degree of resorp-
tion, as well as the risks of the formation of cystic cavities,
which could be dangerous to certain individuals.
Conclusions
In summary, both jellyﬁsh and bovine collagen samples
were accepted by the hosts, and did not appear to induce
any severe immunogenic response. As such, a recovery was
visible in all animals throughout the experiment. Jellyﬁsh
collagen samples JEL #01 and JEL #02 displayed a signiﬁ-
cantly lower histopathology score from start to end of the
study, whereas the bovine collagen control did not. Collagen
implantable sponges were derived for the ﬁrst time from
the R. pulmo jellyﬁsh and showed successful incorporation
in the host. Comparison was made for sponges that were
either uncrosslinked or crosslinked using EDC, and demon-
strated for the ﬁrst time that R. pulmo collagen showed
good resorption and biocompatibility in both crosslinked
and uncrosslinked states. In conclusion, this suggests that
jellyﬁsh collagen is a promising biomaterial for medical
applications, which is tolerated at least equally as well as
bovine collagen.
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